These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34876151)

  • 1. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
    Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
    AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
    Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
    J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study.
    Abe K; Imamura J; Sasaki A; Suzuki T; Kamio S; Obara T; Ito T
    J Pharm Health Care Sci; 2024 Feb; 10(1):13. PubMed ID: 38419093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
    HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
    Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
    AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
    Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
    Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
    Liu Z; Zhao Z; Ma X; Liu S; Xin Y
    BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
    Kanda N; Okamoto K; Okumura H; Mieno M; Sakashita K; Sasahara T; Hatakeyama S
    HIV Med; 2021 Jul; 22(6):457-466. PubMed ID: 33720508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated glomerular filtration rate slopes on tenofovir alafenamide.
    Ibrahim F; Campbell L; Bailey AC; Stockwell S; Waters L; Orkin C; Johnson M; Gompels M; De Burgh-Thomas A; Jones R; Schembri G; Mallon PW; Post FA
    HIV Med; 2020 Oct; 21(9):607-612. PubMed ID: 33021067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
    Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
    J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
    Ikeda M; Wakabayashi Y; Okamoto K; Yanagimoto S; Okugawa S; Moriya K
    AIDS Res Ther; 2021 May; 18(1):30. PubMed ID: 34044856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
    Surial B; Béguelin C; Chave JP; Stöckle M; Boillat-Blanco N; Doco-Lecompte T; Bernasconi E; Fehr J; Günthard HF; Schmid P; Walti LN; Furrer H; Rauch A; Wandeler G;
    J Acquir Immune Defic Syndr; 2020 Oct; 85(2):227-232. PubMed ID: 32925387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study.
    Lok J; Veloz MFG; Byrne R; Carey I; Childs K; Agarwal K; Nelson M
    Clin Ther; 2024 Feb; 46(2):159-163. PubMed ID: 38143153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients.
    Seo JW; Kim K; Jun KI; Kang CK; Moon SM; Song KH; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Choe PG; Park WB; Oh MD
    Infect Chemother; 2020 Sep; 52(3):381-388. PubMed ID: 32757496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study.
    Su PY; Su WW; Hsu YC; Huang SP; Yen HH
    PeerJ; 2021; 9():e12527. PubMed ID: 34820208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.
    Teira R; Diaz-Cuervo H; Aragão F; Muñoz J; Galindo P; Merino M; de la Fuente B; Sepúlveda MA; Domingo P; García J; Castaño M; Ribera E; Geijo P; Romero A; Peraire J; Deig E; Roca B; Martínez E; Estrada V; Montero M; Berenguer J; Espinosa N
    HIV Res Clin Pract; 2021 Jun; 22(3):78-85. PubMed ID: 34410219
    [No Abstract]   [Full Text] [Related]  

  • 19. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.
    Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1673-1683. PubMed ID: 38690711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.